Responsible use of rifampin for the treatment of latent tuberculosis infection
Authors:
Open Access
- 23 June 2019
- journal article
- editorial
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 191 (25) , E678-E679
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in AdultsNew England Journal of Medicine, 2018
- Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysisThe International Journal of Tuberculosis and Lung Disease, 2016
- Towards tuberculosis elimination: an action framework for low-incidence countriesEuropean Respiratory Journal, 2015
- Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007Emerging Infectious Diseases, 2014
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionNew England Journal of Medicine, 2011
- Sputum induction for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011
- High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screeningThorax, 2011
- Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence settingAIDS, 2010
- Direct and indirect costs of tuberculosis among immigrant patients in the NetherlandsBMC Public Health, 2009
- Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review.2007